Management of primary asymptomatic hyperparathyroidism: The SFE (French Society of Endocrinology) Experts' consensus;Prise en charge de l'hyperparathyroïdie primaire asymptomatique: Consensus d'experts de la SFE

Annales d'Endocrinologie

Volumn 67, Issue 1, 2006, Pages 7-12

  Calzada Nocaudie, M ^a   Chanson, P ^a   Conte Devolx, B ^a   Delemer, B ^a   Estour, B ^a   Henry, J F ^a   Houillier, P ^a   Kraimps, J L ^a   Ribot, C ^a   Rohmer, V ^a   Tabarin, A ^a   Verges, B ^a   Vidal Trecan, G ^a   Wemeau, J L ^a   Weryha, G ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; DIURETIC AGENT;

DUAL ENERGY X RAY ABSORPTIOMETRY; HEALTH CARE ORGANIZATION; HUMAN; HYPERPARATHYROIDISM; MORTALITY; REVIEW;

EID: 33645990645     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4266(06)72533-1     Document Type: Review

References (15)

1. Melton III LJ. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res 2002 ; 17 (suppl. 2) : N12-7.
2. Bilezikian JP, Potts JT. Asymptomatic hyperparathyroidism: new issues and new questions-Bridging the past to the future. J Bone Miner Rese 2002 ; 17 (suppl. 2) : N57-67.
3. Bilezikian JP, Potts JT Jr, Fuleihan Gel-H et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st Century. J Clin Endocrinol Metab 2002 ; 87 : 5353-61.
4. Sywak MS, Knowlton ST, Pasieka JL, Parsons LL, Jones J. Do the National Institutes of Health consensus guidelines for parathyroidectomy predict symptom severity and surgical outcome in patients with primary hyperparathyroidism? Surgery 2002 ; 132 : 1013-20.
5. Silvestre SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999 ; 341 : 1249-55.
6. Sudhaker Rao D, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004 ; 89 : 5415-22.
7. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A. Clinical presentation of hyperparathyroidism in Europe- Nationwide cohort analysis on mortality from non malignant causes. J Bone Miner Res 2002 ; 17 (suppl. 2) : N68-74.
8. Vestergaard P, Mosekilde L. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 2003 ; 327 : 530-4.
9. Vergès B. (Sous presse).
10. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003 ; 88 : 1174-8.
11. Khan AA, Bilezikian JP, Kung AW et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004 ; 89 : 3319-25.
12. Peacok M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005 ; 90 : 135-41.
13. Henry JF. (Sous presse).
14. Sejean K, Calmus S, Durand-Zaleski I et al. Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis. Eur J Endocrinol 2005 ; 153 : 915-27.
15. Levey AS, Eckardt K, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005 ; 67 : 2089-100.